ARS PHARMACEUTICALS INC (SPRY)
US82835W1080 - Common Stock
ARS PHARMACEUTICALS INC
NASDAQ:SPRY (9/18/2024, 6:28:38 PM)
After market: 14.05 0 (0%)14.05
+1 (+7.66%)
Company Profile
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 24 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Company Info
ARS PHARMACEUTICALS INC
11682 El Camino Real, Suite 120
San Diego CALIFORNIA
P: 18587719307
Employees: 24
Website: https://ars-pharma.com/
SPRY News
8 days ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference8 days ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare ConferenceSAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk...
9 days ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)9 days ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1...
12 days ago - ChartmillDiscover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
14 days ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including AnaphylaxisSPRY Twits
Here you can normally see the latest stock twits on SPRY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
